Level of 5-fluorodeoxyuridine 5′-monophosphate in cancerous tissue in patients with gastric cancer under preoperative administration of TS-1. A preliminary study

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 3, 2005, Pages 457-462

  Yamamoto, S ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

5 fluorodeoxyuridine 5 monophosphate; Thymidylate synthase; TS 1

Indexed keywords

FLOXURIDINE PHOSPHATE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG TISSUE LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MALE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG COMBINATIONS; FEMALE; FLOXURIDINE; HUMANS; MALE; MIDDLE AGED; OXONIC ACID; PREOPERATIVE CARE; PYRIDINES; STOMACH NEOPLASMS; TEGAFUR; THYMIDYLATE SYNTHASE;

EID: 26244450871     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Ishikawa Y., Kubota T., Otani Y. et al.: Thymidylate synthase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res. 19 (6C) 5635-5640, 1999.
2. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma The 13th Edition 1999.
3. Shirasaka T., Tsukuda M., Inuyama Y., Taguchi T.: New anticancer drug, TS-1 (S-1) - from bench to clinic. Japanese Journal of Cancer and Chemotherapy 28 (6) 855-864, 2001.
4. Hirata K., Horikoshi N., Aiba K. et al.: Pharmacokinetic study of S-1: a novel oral fluorouracil antitumor drug. Clin. Cancer Res. 5:2000-2005, 1999.
5. Murinson D.S., Anderson T., Schwartz H.S. et al.: Competitive binding radioassay 5-fluorodeoxyuridine 5′-monophosphate in tissues. Cancer Res. 39, 2471-2475, 1979.
6. Spears C.P., Gustavsson B.G., Berne M. et al.: Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. Cancer Res. 48, 5894-5900, 1988.
7. Salonga D., Danenberg K.D., Johnson M. et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6:1322-1327, 2000.
8. Ichikawa W., Uetake H., Shirota Y. et al.: Both gene expression for orotate phosphoribosyltransferase and its ratio to dihydropyrimidinedehydrogenase influence outcome following fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. British Journal of Cancer 89 (8), 1486-1492, 2003.
9. Ichikura T., Tomimatsu S., Okusa Y, Yahata T., Uefuji K., Tamakusa S.: Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Cancer Chemother. Pharmocol. 38:401-405, 1996.
10. Miyamoto S., Ochiai A., Boku N. et al.: Discrepancies between the gene expression, protein expression, and enzymatic activity of thymidylate synthase and dihydropyrimidine dehydrogenase in human gastrointestinal cancers and adjacent normal mucosa. Int. J. Oncol. 18:705-713, 2001.
11. Ichikawa W., Uetake H., Shirota Y. et al.: Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine- based chemotherapy for metastatic colorectal cancer. Clin. Cancer Res. 9:786-791, 2003.